NASDAQ: IMRXImmuneering Corp Stock
$1.54+0.09 (+6.21%)
Updated May 23, 2025
IMRX Price
$1.54
Fair Value Price
N/A
Market Cap
$55.42M
52 Week Low
$1.00
52 Week High
$3.83
P/E
-0.78x
P/B
1.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.77M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$54M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IMRX Overview
Immuneering Corporation is a a biopharma focused on the oncology and neuroscience sectors. The company's oncology programs is developing treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Its lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Immuneering was incorporated in 2008 and is headquartered in Cambridge, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IMRX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IMRX
Ranked#314 of 455
Ranked#314 of 455
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $45.93 | A | |
| $8.08 | A | |
| $42.39 | A |
Be the first to know about important IMRX news, forecast changes, insider trades & much more!
IMRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IMRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMRX is good value based on its book value relative to its share price (1.32x), compared to the US Biotechnology industry average (4.29x)
P/B vs Industry Valuation
IMRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IMRX due diligence checks available for Premium users.
Valuation
IMRX fair value
Fair Value of IMRX stock based on Discounted Cash Flow (DCF)
Price
$1.54
Fair Value
$1.93
Undervalued by
20.35%
IMRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IMRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.78x
Industry
-176.38x
Market
21.18x
IMRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.32x
Industry
4.29x
IMRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IMRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.0M
Profit Margin
0%
IMRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$50.7M
Liabilities
$8.8M
Debt to equity
0.21
IMRX's short-term assets ($38.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMRX's short-term assets ($38.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.1M
Investing
-$8.9k
Financing
$13.8M
IMRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IMRX vs Biotech Stocks
Immuneering Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.